ACT-539313 + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Binge-Eating Disorder
Conditions
Binge-Eating Disorder
Trial Timeline
Feb 16, 2021 → Mar 25, 2022
NCT ID
NCT04753164About ACT-539313 + Placebo
ACT-539313 + Placebo is a phase 2 stage product being developed by Idorsia for Binge-Eating Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT04753164. Target conditions include Binge-Eating Disorder.
What happened to similar drugs?
0 of 3 similar drugs in Binge-Eating Disorder were approved
Approved (0) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
12
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04753164 | Phase 2 | Completed |
Competing Products
3 competing products in Binge-Eating Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml + Placebo | Novo Nordisk | Phase 3 | 32 |
| Solriamfetol 75mg, 150 mg, or 300 mg | Axsome Therapeutics | Phase 3 | 44 |
| Solriamfetol 150 mg + Solriamfetol 300 mg + Placebo | Axsome Therapeutics | Phase 3 | 44 |